Data Insights

HT-6184 by Halia Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

HT-6184 is under clinical development by Halia Therapeutics and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...

Data Insights

HT-6184 by Halia Therapeutics for Alzheimer's Disease: Likelihood of Approval

HT-6184 is under clinical development by Halia Therapeutics and currently in Phase I for Alzheimer's Disease. According to GlobalData, Phase...

Data Insights

HT-6184 by Halia Therapeutics for Chronic Inflammation: Likelihood of Approval

HT-6184 is under clinical development by Halia Therapeutics and currently in Phase I for Chronic Inflammation. According to GlobalData, Phase...

Data Insights

HT-6184 by Halia Therapeutics for Post-Operative Pain: Likelihood of Approval

HT-6184 is under clinical development by Halia Therapeutics and currently in Phase II for Post-Operative Pain. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - HT-6184 in Post-Operative Pain

Data Insights

HT-6184 by Halia Therapeutics for Anemia: Likelihood of Approval

HT-6184 is under clinical development by Halia Therapeutics and currently in Phase II for Anemia. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - HT-6184 in Anemia

Data Insights

HT-6184 by Halia Therapeutics for Acute Inflammation: Likelihood of Approval

HT-6184 is under clinical development by Halia Therapeutics and currently in Phase II for Acute Inflammation. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - HT-6184 in Acute Inflammation